GSK Implements Genedata Biologics as Antibody Discovery Platform
Genedata Biologics integrates GlaxoSmithKline’s Biopharm Discovery workflows across multiple Biopharm R&D groups and sites
May 28, 2014
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Biopharm R&D at GlaxoSmithKline (GSK) has selected Genedata Biologics™ as a key R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.
The system records, manages, and processes data from GSK’s diverse antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies, including proprietary ones. In addition, Genedata Biologics helps to improve data quality, improve efficiency through upload and export of instrument data, increase experimental throughput, and streamline workflows.
Genedata supports the deployment and roll-out of the Genedata Biologics system, its integration into GSK’s R&D environment, and its use of Biopharm’s high-throughput automation platforms. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats such as GSK’s domain antibodies and other proprietary molecules and technologies.
As an integrated and scalable IT platform, Genedata Biologics makes it easy to share results across many groups involved in R&D projects. The system’s built-in business logic supports the full diversity of GSK’s complex and evolving antibody discovery processes.
“We are honored to have GSK, a global leader in biopharmaceuticals, choose Genedata Biologics as the platform to support their biopharmaceutical R&D processes,” said Dr. Othmar Pfannes, CEO of Genedata. “The collaboration with GSK is another milestone on our path to establish Genedata Biologics worldwide as the platform of choice to streamline the discovery and development of novel biopharmaceuticals. We will continue to expand the platform to meet the quickly emerging new requirements in support of this highly innovative and important field.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
The collaboration with GSK is another milestone on our path to establish Genedata Biologics worldwide as the platform of choice to streamline the discovery and development of novel biopharmaceuticals